Oct. 29, 2022
GCN2: A Viable Cancer Immunotherapy Target for MDSCs?
compound 39
oral GCN2 kinase inhibitor TGI in LL2 syngeneic mouse model SAR opt. from literature starting point J. Med. Chem., Sep 20, 2022 RAPT Therapeutics, South San Francisco, CA